MD3458039T2 - Combinație triplă de antagoniști ai receptorilor 5-HT6 puri, inhibitori ai acetilcolinesterazei și antagonistul receptorului NMDA - Google Patents
Combinație triplă de antagoniști ai receptorilor 5-HT6 puri, inhibitori ai acetilcolinesterazei și antagonistul receptorului NMDAInfo
- Publication number
- MD3458039T2 MD3458039T2 MDE20190349T MDE20190349T MD3458039T2 MD 3458039 T2 MD3458039 T2 MD 3458039T2 MD E20190349 T MDE20190349 T MD E20190349T MD E20190349 T MDE20190349 T MD E20190349T MD 3458039 T2 MD3458039 T2 MD 3458039T2
- Authority
- MD
- Moldova
- Prior art keywords
- pure
- receptor antagonist
- receptor antagonists
- acetylcholinesterase inhibitors
- nmda
- Prior art date
Links
- 229940099433 NMDA receptor antagonist Drugs 0.000 title abstract 4
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 title abstract 4
- 108091005435 5-HT6 receptors Proteins 0.000 title abstract 3
- 239000000544 cholinesterase inhibitor Substances 0.000 title abstract 3
- 229940044551 receptor antagonist Drugs 0.000 title abstract 3
- 239000002464 receptor antagonist Substances 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 abstract 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Prezenta invenţie se referă la o combinaţie triplă de antagonişti ai receptorilor 5-HT6, puri , inhibitori al acetilcolinesterazei şi antagonistul receptorului NMDA. De asemenea, prezenta invenţie furnizează antagonişti ai receptorului 5-HT6 pur (5-HT6R), sau sarea (lor) acceptabilă farmaceutic a acestora în combinaţie cu sau ca adjuvant la inhibitorul acetilcolinesterazei şi antagonist al receptorului N-metil-D-aspartatc (NMDA) şi utilizarea lor în tratamentul tulburărilor cognitive. Prezenta invenţie furnizează în plus compoziţia farmaceutică care conţine combinaţia menţionată.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201641017204 | 2016-05-18 | ||
PCT/IB2016/054672 WO2017199070A1 (en) | 2016-05-18 | 2016-08-03 | Triple combination of pure 5-ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor antagonist |
Publications (1)
Publication Number | Publication Date |
---|---|
MD3458039T2 true MD3458039T2 (ro) | 2020-10-31 |
Family
ID=56896730
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MDE20190349T MD3458039T2 (ro) | 2016-05-18 | 2016-08-03 | Combinație triplă de antagoniști ai receptorilor 5-HT6 puri, inhibitori ai acetilcolinesterazei și antagonistul receptorului NMDA |
Country Status (28)
Country | Link |
---|---|
US (1) | US11253514B2 (ro) |
EP (1) | EP3458039B1 (ro) |
JP (1) | JP6629464B2 (ro) |
KR (1) | KR102016120B1 (ro) |
CN (1) | CN109152751A (ro) |
AU (1) | AU2016407426B2 (ro) |
BR (1) | BR112018073410A2 (ro) |
CA (1) | CA3023836C (ro) |
CY (1) | CY1123644T1 (ro) |
DK (1) | DK3458039T3 (ro) |
EA (1) | EA038087B1 (ro) |
ES (1) | ES2815555T3 (ro) |
HK (1) | HK1258022A1 (ro) |
HR (1) | HRP20201412T1 (ro) |
HU (1) | HUE052077T2 (ro) |
IL (1) | IL262920B (ro) |
LT (1) | LT3458039T (ro) |
MA (1) | MA45002B1 (ro) |
MD (1) | MD3458039T2 (ro) |
MX (1) | MX2018014184A (ro) |
NZ (1) | NZ747797A (ro) |
PL (1) | PL3458039T3 (ro) |
PT (1) | PT3458039T (ro) |
RS (1) | RS60849B1 (ro) |
SG (1) | SG11201809726UA (ro) |
SI (1) | SI3458039T1 (ro) |
WO (1) | WO2017199070A1 (ro) |
ZA (1) | ZA201807310B (ro) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2019015606A (es) * | 2017-07-03 | 2022-09-07 | Suven Life Sciences Ltd | Nuevos usos de un antagonista del receptor 5-ht6 puro. |
US20220409614A1 (en) * | 2019-12-02 | 2022-12-29 | Suven Life Sciences Limited | Treating behavioral and psychological symptoms in dementia patients |
CA3162938A1 (en) * | 2019-12-02 | 2021-06-10 | Suven Life Sciences Limited | Methods for treating behavioral and psychological symptoms in patients with dementia |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE414519T1 (de) * | 2002-05-31 | 2008-12-15 | Lundbeck & Co As H | Kombination aus einem nmda-antagonist und acetylcholinesterase-hemmern zur behandlung der alzheimer-krankheit |
KR100818508B1 (ko) * | 2002-11-28 | 2008-03-31 | 수벤 라이프 사이언시스 리미티드 | 세로토닌 수용체 친화력을 가지는 엔-아릴술포닐-3-치환인돌, 그 제조방법 및 그를 포함하는 약제학적 조성물 |
DK2521714T3 (en) * | 2010-01-05 | 2015-10-19 | Suven Life Sciences Ltd | Aromatic sulfone compositions useful in the treatment of central nervous disorders |
PT3077375T (pt) * | 2013-12-02 | 2017-09-05 | Suven Life Sciences Ltd | Processo para produção em massa de 1-[(2- bromofenil)sulfonilo]-5-metoxi-3-[(4-metilo-1- piperazinil)metilo]-dimesilato de 1h-indol mono-hidratado |
WO2015158313A1 (en) * | 2014-04-19 | 2015-10-22 | Sunshine Lake Pharma Co., Ltd. | Sulfonamide derivatives and pharmaceutical applications thereof |
-
2016
- 2016-08-03 SI SI201630909T patent/SI3458039T1/sl unknown
- 2016-08-03 CN CN201680085589.7A patent/CN109152751A/zh active Pending
- 2016-08-03 ES ES16763575T patent/ES2815555T3/es active Active
- 2016-08-03 US US16/097,752 patent/US11253514B2/en active Active
- 2016-08-03 AU AU2016407426A patent/AU2016407426B2/en active Active
- 2016-08-03 JP JP2018559327A patent/JP6629464B2/ja active Active
- 2016-08-03 RS RS20201045A patent/RS60849B1/sr unknown
- 2016-08-03 PL PL16763575T patent/PL3458039T3/pl unknown
- 2016-08-03 MD MDE20190349T patent/MD3458039T2/ro unknown
- 2016-08-03 KR KR1020187035888A patent/KR102016120B1/ko active IP Right Grant
- 2016-08-03 EA EA201892528A patent/EA038087B1/ru unknown
- 2016-08-03 MX MX2018014184A patent/MX2018014184A/es unknown
- 2016-08-03 BR BR112018073410-1A patent/BR112018073410A2/pt not_active Application Discontinuation
- 2016-08-03 PT PT167635754T patent/PT3458039T/pt unknown
- 2016-08-03 EP EP16763575.4A patent/EP3458039B1/en active Active
- 2016-08-03 HU HUE16763575A patent/HUE052077T2/hu unknown
- 2016-08-03 MA MA45002A patent/MA45002B1/fr unknown
- 2016-08-03 DK DK16763575.4T patent/DK3458039T3/da active
- 2016-08-03 WO PCT/IB2016/054672 patent/WO2017199070A1/en unknown
- 2016-08-03 CA CA3023836A patent/CA3023836C/en active Active
- 2016-08-03 NZ NZ747797A patent/NZ747797A/en unknown
- 2016-08-03 SG SG11201809726UA patent/SG11201809726UA/en unknown
- 2016-08-03 LT LTEP16763575.4T patent/LT3458039T/lt unknown
-
2018
- 2018-10-31 ZA ZA2018/07310A patent/ZA201807310B/en unknown
- 2018-11-11 IL IL262920A patent/IL262920B/en active IP Right Grant
-
2019
- 2019-01-10 HK HK19100393.2A patent/HK1258022A1/zh unknown
-
2020
- 2020-09-03 HR HRP20201412TT patent/HRP20201412T1/hr unknown
- 2020-09-04 CY CY20201100834T patent/CY1123644T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MD3507289T2 (ro) | Modulatori alosterici pozitivi ai receptorilor muscarinici M1 | |
MX2016011632A (es) | Derivados de azaspiro como antagonistas de trpm8. | |
MD3288940T2 (ro) | Azabenzimidazoli și utilizarea lor ca modulatori ai receptorilor AMPA | |
WO2016109217A3 (en) | Btk inhibitors | |
PH12016502353A1 (en) | Pharmaceutical composition | |
JOP20190233A1 (ar) | نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون | |
TW201613577A (en) | Pharmaceutical combinations | |
EA201792057A1 (ru) | Конденсированные бициклические гетероарильные производные с активностью ингибиторов пролилгидроксилазы | |
MX2017011978A (es) | Analogos deuterados de etifoxina, sus derivados y usos de estos. | |
MD3303331T2 (ro) | Modulatori alosterici pozitivi ai receptorilor muscarinici M1 | |
MD3355890T2 (ro) | Inhibitori de kalikreină plasmatică umană | |
WO2018027084A3 (en) | Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer | |
MD3484467T2 (ro) | Combinație de antagoniști ai receptorilor 5-HT6 puri cu inhibitori ai acetilcolinesterazei | |
MX2020010568A (es) | Derivados de urea ciclica fusionada como antagonista de crhr2. | |
MD3458039T2 (ro) | Combinație triplă de antagoniști ai receptorilor 5-HT6 puri, inhibitori ai acetilcolinesterazei și antagonistul receptorului NMDA | |
MD3347349T2 (ro) | Derivați de fluoroindol ca modulatori alosterici pozitivi ai receptorilor muscarinici M1 | |
PH12021550549A1 (en) | Dp antagonist | |
EA201791480A1 (ru) | Новые производные бензимидазола в качестве антигистаминных агентов | |
PH12016501625A1 (en) | Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists | |
MX2018013969A (es) | Combinacion de antagonistas del receptor 5-ht6 puro con un antagonista del receptor nmda. | |
PH12021550143A1 (en) | Pyridopyrimidines as histamine h4-receptor inhibitors | |
PH12017501736A1 (en) | Indole derivatives | |
MD3500306T2 (ro) | Combinație triplă de agonist invers al receptorului histaminic 3, inhibitor al acetilcolinesterazei și antagonist al receptorului NMDA | |
NZ750150A (en) | Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors | |
TN2017000248A1 (en) | Cgrp antagonist peptides |